Concurrent paclitaxel or/and carboplatin with radiotherapy for stageⅢnon-small cell lung cancer
WANG Xiao-zhen,WANG Lu-hua,JI Wei,ZHOU Zong-mei,LIANG Jun,OU Guang-fei,ZHANG Hong-xing,FENG Qin-fu,YIN Wei-bo
DOI: https://doi.org/10.3760/j.issn:1004-4221.2006.04.007
2006-01-01
Abstract:Objective To study the toxicity and efficacy of concurrent paclitaxel or/and carboplatin with radiotherapy for stageⅢnon-small cell lung cancer(NSCLC).Methods Forty-one patients pathologically diagnosed as suffering from NSCLC(Ⅲa:17,Ⅲb:24)received concurrent 60-70 Gy conventional fractionated external beam radiotherapy with chemotherapy:paclitaxel(4S mg/m~2,n=13);or combined with carboplatin(AUC =2,n=28),once weekly.Results Thirty-seven patients received a total dose of 60-72 Gy,two received 54 Gy and two received 56 Gy.Thirty-eight patients received 4-6 weeks of chemotherapy,while three patients received only 2 weeks of chemotherapy.Two patients experienced grade 3 and 4 neutropenia,4 grade 3 radiation esophagitis,6≥grade 2 radiation pneumonitis and one grade 3 mucositis.The total response rate(CB+PR)was 78%,with a median foUow-up time of 17.2 months.The median survival time was 16.5 months(20.0 m for stageⅢa,15.8 m forⅢb,).The overall 1-,2-and 3-year survival rate was 69%,34% and 34%,respectively.The median time of recurrence-free survival was 57.8 months.The 1-and 2-year recurrence-free survival(RFS)rate was 85% and 85%,respectively.The patterns of failure were 4 intra-field recurrence,1 local and extra-field regional recurrence,1 extra-field regional recurrence,2 carcinomatous phural effusion and 12 distant metastasis. Conclusions Concurrent chemoradiotherapy with paclitaxel and/or carboplatin can well be tolerated,with a relatively good short and remote effectiveness.The major pattern of failure is distant metastasis.High radiation dose (＜66 Gy)may provide a more satisfactory powerful effectiveness.